




Fact Sheet

XIENCE V[®] Drug Eluting Stent

Key Facts

- The XIENCE V[®] Everolimus Eluting Coronary Stent System is the market-leading drug eluting stent around the world¹.
- Each aspect of XIENCE V's design, from the thin struts to the flexible delivery system to the drug and polymer, was carefully engineered for optimal deliverability and for effective use.
- XIENCE V has demonstrated superiority against Taxus Express in the primary endpoints of SPIRIT II and SPIRIT III².
- More than 35,000 XIENCE V patients have been studied in clinical trials around the world.



Overview

Abbott's XIENCE V Everolimus Eluting Coronary Stent System is approved for use in the United States, Latin America, Europe, China, Japan and other international markets.

Drug eluting stents are used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug in a controlled manner which prevents restenosis, or the renarrowing of an artery following the stent procedure.

Proven Design

XIENCE V is built upon the cobalt chromium MULTI-LINK VISION[®] Coronary Stent System, the most widely used stent platform in the world¹. More than four million of Abbott's cobalt chromium stents have been implanted worldwide³.

¹ Q1 2010 market share data on file at Abbott Vascular

² Source: XIENCE V IFU

³ Data on file with Abbott Vascular

Each element of XIENCE V – the drug that is used, the concentration of the drug, the rate of elution, the composition of the polymer coating, the stent platform and the delivery system – is important in overall clinical safety and efficacy outcomes.

- XIENCE V has one of the thinnest drug eluting stent platform available, with a flexible design allowing it to be delivered to the narrowed or blocked artery.
- The polymer coating on XIENCE V facilitates a steady release of the drug everolimus.
- Everolimus has been shown to reduce tissue growth and inflammation – two factors tied to restenosis, or the renarrowing of an artery following a stent procedure.

Excellent Clinical Data

The outstanding data for XIENCE V includes long-term efficacy and safety results in several pivotal trials, and among the SPIRIT family of trials.

In the SPIRIT III U.S. trial, XIENCE V demonstrated a low rate (0.2% based on binary event rates) of very late stent thrombosis (blood clots) with no additional events between two and three years, and a 43 percent reduction in the risk of major adverse cardiac events (MACE) compared to the TAXUS[®] Express^{2™} Paclitaxel-Eluting Coronary Stent System at three years.

The SPIRIT Family of Trials

Abbott is committed to the long term follow-up of patients in XIENCE V studies for years to come. The SPIRIT Clinical Trial Program includes more than 10 different trials to evaluate XIENCE V for the treatment of coronary artery disease (CAD). These studies include:

- SPIRIT FIRST – A first-in-man study comparing XIENCE V with the MULTI-LINK VISION metallic stent system in 60 patients
- SPIRIT II – A 300 patient randomized, single-blind prospective clinical trial evaluating XIENCE V versus TAXUS (Express² and Liberté) in Europe and Asia Pacific
- SPIRIT III – A large-scale pivotal clinical trial comparing XIENCE V to TAXUS (Express²) in 1,002 patients in the United States
- SPIRIT III Japan – A registry of 88 patients in Japan
- SPIRIT IV – A 3,690 patient continued access trial conducted in the United States to evaluate the safety and efficacy of XIENCE V compared to TAXUS (Express²) in a more complex CAD patient population
- SPIRIT V – An international single arm trial that provides additional clinical experience with XIENCE V in 2,700 patients at approximately 100 clinical sites in Europe, Asia and Canada
- SPIRIT V Diabetes – An international randomized clinical trial comparing XIENCE V to the TAXUS (Liberté) in 300 CAD patients with diabetes

- XIENCE V SPIRIT WOMEN – The world's first drug eluting stent trial to study only women, evaluating the performance of XIENCE V in 2,000 female patients in over 100 international sites.
- XIENCE V USA – As part of Abbott's commitment to advancing the treatment of vascular disease, this post-market registry will evaluate the safety of XIENCE V in more than 8,000 patients with follow-up out to five years
- XIENCE V INDIA – Similar to XIENCE V USA, this post-market registry will evaluate clinical outcomes in approximately 1,000 patients in India with follow up out to two years
- XIENCE V JAPAN – This post-market registry will evaluate clinical outcomes in approximately 1,900 patients in Japan with follow up out to five years
- SPIRIT SMALL VESSEL – A 150-patient registry evaluating a smaller size XIENCE V (2.25mm) in patients with smaller vessels in the United States

#

TAXUS® is a trademark of Boston Scientific Corporation.

Additional information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.